A META-ANALYSIS OF PIPERACILLIN/TAZOBACTAM VERSUS CEFEPIME TREATMENT IN CANCER PATIENTS WITH FEBRILE NEUTROPENIA

被引:0
作者
Zhang Weidong [1 ]
Xiao Chun [2 ]
Zhou Sixin [3 ]
Wang Rui [1 ]
Wang Li [1 ]
Jia Liping [1 ]
Ma Jinqiu [1 ]
Wang Na [1 ]
机构
[1] First Hosp Qinhuangdao, Qinhuangdao 066000, Peoples R China
[2] PLA Rocket Force, Gen Hosp, Dept Gen Surg, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing 100853, Peoples R China
来源
BIOSCIENCE JOURNAL | 2016年 / 32卷 / 06期
关键词
Meta-analysis; Piperacillin/Tazobactam; Cefepime; Febrile neutropenia; Cancer; STEM-CELL TRANSPLANTATION; EMPIRICAL-TREATMENT; OPEN-LABEL; MONOTHERAPY; TAZOBACTAM; MULTICENTER; MANAGEMENT; THERAPY; FEVER; CHEMOTHERAPY;
D O I
暂无
中图分类号
S [农业科学];
学科分类号
09 ;
摘要
Febrile neutropenia (FN) causes a major threat to cancer patients after chemotherapy. Broad-spectrum antibiotic treatment is a well-established practice for febrile neutropenia. Piperacillin/Tazobactam (P/T) is the frequently used antibiotic in most of FN cases, whereas the use of cefepime remains unclear regarding its potential risk. However, little systematic analysis has been conducted about comparison between these two drugs. Thus, we undertook this meta-analysis to compare these two monotherapies for febrile neutropenia. Through searching Pubmed, Google scholar, Medline databases, EMBASE, OvidSP, ScienceDirect, Web of science, and China Journal Net (CJN) databases, we used the keywords "(Piperacillin/Tazobactam AND cefepime) AND (febrile neutropenia) AND (cancer or tumor)". Only studies with randomized controlled trials were included in the meta-analysis. We screened out a total number of seven clinical trials. This meta-analysis supported that P/T treatment was superior to cefepime treatment based on the average OR comparison, without statistical significance (OR = 1.27, 95% confidence interval = 0.98 to 1.64, p = 0.07). We further divided the seven studies into two subgroups based on age and treatment time. The young group (age <= 19) showed no significant difference (OR = 1.10, p = 0.65). While the old group (age > 19) showed that P/T treatment was better than cefepime with statistical difference (OR = 1.44, p = 0.05). The short-term group (time <= 3 ds) showed P/T treatment was better than cefepime with statistical difference (OR = 1.40, p = 0.05). While in the long-term group (time > 5 ds), there was no significant difference between P/T and cefepime therapy (OR = 1.06, p = 0.79) Asymmetry in Funnel plots indicated no publication bias (CHI2 = 1.47, I-2 = 0%, and p-value = 0.96) in this meta-analysis. It would be a good clinical trial to use P/T treatment to cure FN in cancer patients compared with cefepime treatment, especially in adult patients or patients with a short-term treatment period. This meta-analysis is practically important during antibiotic treatment in FN management.
引用
收藏
页码:1669 / 1678
页数:10
相关论文
共 50 条
[41]   Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients [J].
Hamidah, A. ;
Rizal, A. M. ;
Nordiah, A. J. ;
Jamal, R. .
SINGAPORE MEDICAL JOURNAL, 2008, 49 (01) :26-30
[42]   Pegfilgrastim on febrile neutropenia in pediatric and adolescent cancer patients: a systematic review and meta-analysis [J].
Zhu, Xia ;
Zhang, Weiling ;
Zhang, Yi ;
Wang, Yizhuo ;
Hu, Huimin ;
Li, Jing ;
Zhou, Yan ;
Han, Tao ;
Huang, Dongsheng .
HEMATOLOGY, 2023, 28 (01)
[43]   Assessing the risk of false positive serum galactomannan among patients receiving piperacillin/tazobactam for febrile neutropenia [J].
Demiraslan, Hayati ;
Atalay, M. Altay ;
Eren, Esma ;
Demir, Koray ;
Kaynar, Leylagul ;
Koc, A. Nedret ;
Doganay, Mehmet .
MEDICAL MYCOLOGY, 2017, 55 (05) :535-540
[44]   Prognostic factors for risk stratification of adult cancer patients with chemotherapy-induced febrile neutropenia: A systematic review and meta-analysis [J].
Lee, Yee Mei ;
Lockwood, Craig .
INTERNATIONAL JOURNAL OF NURSING PRACTICE, 2013, 19 (06) :557-576
[45]   A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia [J].
Manji, Arif ;
Lehrnbecher, Thomas ;
Dupuis, L. Lee ;
Beyene, Joseph ;
Sung, Lillian .
SUPPORTIVE CARE IN CANCER, 2012, 20 (10) :2295-2304
[46]   Treatment of febrile neutropenia episodes in children, with a piperacillin-tazobactam and netilmicin combination [J].
Fouyssac, F ;
Salmon, A ;
Mansuy, L ;
Schmitt, C ;
Bordigoni, P ;
Chastagner, P .
MEDECINE ET MALADIES INFECTIEUSES, 2005, 35 (06) :357-362
[47]   Dose Individualization of Cefepime for Febrile Neutropenia in Patients With Lymphoma or Multiple Myeloma: Implications for Therapeutic Drug Monitoring [J].
Oda, Kazutaka ;
Yamaguchi, Ayami ;
Matsumoto, Naoya ;
Nakata, Hirotomo ;
Higuchi, Yusuke ;
Nosaka, Kisato ;
Jono, Hirofumi ;
Saito, Hideyuki .
THERAPEUTIC DRUG MONITORING, 2024, 46 (01) :80-88
[48]   A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia [J].
Bauduer, F ;
Cousin, T ;
Boulat, O ;
Rigal-Huguet, F ;
Molina, L ;
Fegueux, N ;
Jourdan, E ;
Boiron, JM ;
Reiffers, J .
LEUKEMIA & LYMPHOMA, 2001, 42 (03) :379-386
[49]   The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study [J].
Fujita, Masaki ;
Matsumoto, Takemasa ;
Inoue, Yuuichi ;
Wataya, Hiroshi ;
Takayama, Koichi ;
Ishida, Masayuki ;
Ebi, Noriyuki ;
Kishimoto, Junji ;
Ichinose, Yukito .
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2016, 22 (04) :235-239
[50]   Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials [J].
Vidal, L ;
Paul, M ;
Ben dor, I ;
Soares-Weiser, K ;
Leibovici, L .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (01) :29-37